Advertisement

Bone turnover markers are differentially affected by pre-analytical handling

  • G.L. Christensen
  • J.R. Halgreen
  • M. Milenkovski
  • A. Köse
  • N. Quardon
  • N.R. JørgensenEmail author
Short Scientific Communication

Abstract

Summary

Given that bone turnover markers are often shipped to central laboratories, it is essential to be aware of factors that will affect stability. We have evaluated how sample type, time before separation of blood samples, and time between separation and analysis affect the stability of four bone turnover markers.

Introduction

Bone turnover markers are often shipped to central laboratories for analysis, which require knowledge of the stability of the markers of interest in different sample materials. The aim of the current study was to evaluate how time before separation of blood samples and time between separation and analysis affect the stability of four bone turnover markers in serum and plasma samples.

Methods

Serum, EDTA, and Lithium heparin (LiHep) plasma samples from seven osteoporosis patients and three healthy controls were collected and stored at room temperature for up to 72 h before separation and analysis. After separation, samples were stored at room temperature for up to 72 h and re-analyzed. The bone turnover markers N-terminal pro-collagen type 1 extension pro-peptide (P1NP), bone-specific alkaline phosphatase (BAP), C-terminal teleopeptide cross links of collagen type 1 (CTX), and osteocalcin (OC) were analyzed using the automated iSYS IDS platform.

Results

P1NP and BAP were stable in both plasma and serum for 72 h before centrifugation. CTX levels were higher in EDTA plasma at all time points compared to LiHep plasma and serum. The use of EDTA plasma prolonged the stability of CTX as compared to LiHep plasma and serum. Osteocalcin showed high tendency to degrade in all sample types and concentrations were significantly lower after 24 h of storage.

Conclusions

For the bone turnover markers P1NP and BAP, the use of both plasma and serum is recommended. Samples for CTX analysis should be taken as EDTA plasma. Samples for osteocalcin analysis can be taken in either type of plasma or serum, but should be analyzed within 3 h or preserved at − 18 °C.

Keywords

BAP Bone turnover markers CTX Osteocalcin Pre-analytical P1NP Stability 

Notes

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Conflict of interest

None.

References

  1. 1.
    Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R, National Osteoporosis F (2014) Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359–2381CrossRefGoogle Scholar
  2. 2.
    Nih Consensus Development Panel on Osteoporosis Prevention D, Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785–795CrossRefGoogle Scholar
  3. 3.
    Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRefGoogle Scholar
  4. 4.
    Deal CL (2001) Using bone densitometry to monitor therapy in treating osteoporosis: pros and cons. Curr Rheumatol Rep 3:233–239CrossRefGoogle Scholar
  5. 5.
    Vasikaran S, Eastell R, Bruyere O et al (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420CrossRefGoogle Scholar
  6. 6.
    Jørgensen NR, Mollehave LT, Hansen YBL, Quardon N, Lylloff L, Linneberg A (2017) Comparison of two automated assays of BTM (CTX and P1NP) and reference intervals in a Danish population. Osteoporos Int 28:2103–2113CrossRefGoogle Scholar
  7. 7.
    Chubb SA, Mandelt CD, Vasikaran SD (2015) Comparison of results from commercial assays for plasma CTX: the need for harmonization. Clin Biochem 48:519–524CrossRefGoogle Scholar
  8. 8.
    Szulc P, Naylor K, Hoyle NR, Eastell R, Leary ET, National Bone Health Alliance Bone Turnover Marker P (2017) Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability. Osteoporos Int 28:2541–2556CrossRefGoogle Scholar
  9. 9.
    Stokes FJ, Ivanov P, Bailey LM, Fraser WD (2011) The effects of sampling procedures and storage conditions on short-term stability of blood-based biochemical markers of bone metabolism. Clin Chem 57:138–140CrossRefGoogle Scholar
  10. 10.
    Morovat A, Catchpole A, Meurisse A, Carlisi A, Bekaert AC, Rousselle O, Paddon M, James T, Cavalier E (2013) IDS iSYS automated intact procollagen-1-N-terminus pro-peptide assay: method evaluation and reference intervals in adults and children. Clin Chem Lab Med 51:2009–2018CrossRefGoogle Scholar
  11. 11.
    Broyles DL, Nielsen RG, Bussett EM, Lu WD, Mizrahi IA, Nunnelly PA, Ngo TA, Noell J, Christenson RH, Kress BC (1998) Analytical and clinical performance characteristics of Tandem-MP Ostase, a new immunoassay for serum bone alkaline phosphatase. Clin Chem 44:2139–2147Google Scholar
  12. 12.
    Lippi G, Brocco G, Salvagno GL, Montagnana M, Guidi GC, Schmidt-Gayk H (2007) Influence of the sample matrix on the stability of beta-CTX at room temperature for 24 and 48 hours. Clin Lab 53:455–459Google Scholar
  13. 13.
    Wheater G, Goodrum C, Tuck SP, Datta HK, van Laar JM (2014) Method-specific differences in beta-isomerised carboxy-terminal cross-linking telopeptide of type I collagen and procollagen type I amino-terminal propeptide using two fully automated immunoassays. Clin Chem Lab Med 52:e135–e138CrossRefGoogle Scholar
  14. 14.
    Power MJ, O’Dwyer B, Breen E, Fottrell PF (1991) Osteocalcin concentrations in plasma prepared with different anticoagulants. Clin Chem 37:281–284Google Scholar
  15. 15.
    Jaouhari J, Schiele F, Dragacci S, Tarallo P, Siest JP, Henny J, Siest G (1992) Avidin-biotin enzyme immunoassay of osteocalcin in serum or plasma. Clin Chem 38:1968–1974Google Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  1. 1.Department of Clinical BiochemistryRigshospitaletCopenhagenDenmark
  2. 2.OPEN, Odense Patient Data Explorative Network, Odense University Hospital/Institute of Clinical ResearchUniversity of Southern DenmarkOdenseDenmark

Personalised recommendations